The Therapeutic Benefit of Bacterial Membrane Vesicles.
The Therapeutic Benefit of Bacterial Membrane Vesicles.
复制标题
DOI：
10.3390/ijms18061287
复制
发表时间：
2017-06-16
影响因子：
5.6
通讯作者：
Kaparakis-Liaskos M
中科院分区：
文献类型：
--
作者：
Bitto NJ;Kaparakis-Liaskos M
近年来，真核生物细胞外囊泡的治疗潜力引起了人们的强烈兴趣。然而，对它们的细菌对应物的治疗应用的研究，被称为细菌膜囊泡，才刚刚开始受到重视。革兰氏阳性和革兰氏阴性细菌的膜囊泡（MVs）在治疗发展中具有显著的优势，包括大规模、成本有效的生产和易于分子操作以显示外源抗原。mv的纳米颗粒大小使其能够在许多组织类型中传播，并且在疫苗设计中可以利用其天然免疫原性和自我调节能力来诱导细胞介导和体液免疫。此外，通过显示表面受体将mv靶向到特定组织的能力提高了它们作为靶向mv抗癌治疗的潜在用途。这篇综述讨论了MV研究的最新进展，特别强调了MV在治疗设计中应用的令人兴奋的新可能性。
The therapeutic potential of extracellular vesicles from eukaryotes has gained strong interest in recent years. However, research into the therapeutic application of their bacterial counterparts, known as bacterial membrane vesicles, is only just beginning to be appreciated. Membrane vesicles (MVs) from both Gram-positive and Gram-negative bacteria offer significant advantages in therapeutic development, including large-scale, cost effective production and ease of molecular manipulation to display foreign antigens. The nanoparticle size of MVs enables their dissemination through numerous tissue types, and their natural immunogenicity and self-adjuvanting capability can be harnessed to induce both cell-mediated and humoral immunity in vaccine design. Moreover, the ability to target MVs to specific tissues through the display of surface receptors raises their potential use as targeted MV-based anti-cancer therapy. This review discusses recent advances in MV research with particular emphasis on exciting new possibilities for the application of MVs in therapeutic design.